ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

TNGX Tango Therapeutics Inc

8,93
0,54 (6,44%)
15 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Tango Therapeutics Inc TNGX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,54 6,44% 8,93 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
8,34 8,08 9,12 8,93 8,39
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
07.6.202423:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.6.202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.6.202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.6.202422:06EDGAR2Form 8-K - Current report
05.6.202413:00BWTango Therapeutics to Present at the Goldman Sachs 45th..
23.5.202415:18PRNUSMedivir´s licensee, Tango Therapeutics, has discontinued..
23.5.202413:18EDGAR2Form 8-K - Current report
23.5.202413:00BWTango Therapeutics Announces Discontinuation of TNG348..
08.5.202413:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.5.202413:14EDGAR2Form 8-K - Current report
08.5.202413:00BWTango Therapeutics Reports First Quarter 2024 Financial..
01.4.202422:48BWTango Therapeutics Announces Inducement Grants Under Nasdaq..
18.3.202412:00BWTango Therapeutics Reports Fourth Quarter and Full Year 2023..
06.3.202413:00BWTango Therapeutics to Participate in Upcoming Investor..
05.3.202422:47GLOBETango Therapeutics to Highlight Preclinical Data on..
09.2.202403:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202403:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.2.202413:00EDGAR2Form 8-K - Current report
05.2.202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202413:00GLOBETango Therapeutics to Present at the Guggenheim Healthcare..
05.1.202422:05GLOBETango Therapeutics Announces Inducement Grants Under Nasdaq..
04.1.202408:47PRNUSMedivir´s licensee, Tango Therapeutics, has dosed the first..
03.1.202413:00GLOBETango Therapeutics Announces First Patient Dosed in Phase..
13.11.202313:00GLOBETango Therapeutics to Highlight Preclinical Data on PRMT5..
08.11.202313:29EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202313:07EDGAR2Form 8-K - Current report
08.11.202313:00GLOBETango Therapeutics Reports Third Quarter 2023 Financial..
07.11.202313:00GLOBETango Therapeutics to Present at the Jefferies London..
02.11.202321:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.10.202323:23EDGAR2Form SC 13D/A - General statement of acquisition of..
18.9.202313:00GLOBETango Therapeutics to Highlight Preclinical Data on..
12.9.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
06.9.202313:00GLOBETango Therapeutics Announces FDA Clearance of..
05.9.202313:00GLOBETango Therapeutics to Participate in the H.C. Wainwright..
01.9.202313:34EDGAR2Form S-3 - Registration statement under Securities Act of..
31.8.202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.8.202322:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
30.8.202312:04EDGAR2Form 8-K - Current report
29.8.202323:08GLOBETango Therapeutics Announces Updates to Its Board of..
28.8.202313:00GLOBEMedicenna Announces the Appointment of Jeff Caravella as..
21.8.202322:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16.8.202322:40EDGAR2Form SC 13D/A - General statement of acquisition of..
10.8.202313:24EDGAR2Form 8-K - Current report
10.8.202313:00GLOBETango Therapeutics Announces $80 million Private Placement..
07.8.202313:57EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.8.202313:25EDGAR2Form 8-K - Current report
07.8.202313:00GLOBETango Therapeutics Reports Second Quarter 2023 Financial..
24.7.202313:00GLOBETango Therapeutics Announces First Patient Dosed in TNG260..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock